Skin pain is a separate and highly bothersome symptom for children with AD.
Study suggests that treatment with abrocitinib 200 mg QD results in a greater and more rapid response vs dupilumab, as assessed using stringent endpoints.
Rapid, clinically meaningful, and continual improvement in itch observed with ruxolitinib cream for patients with atopic dermatitis.
Case series suggests efficacy of itraconazole for the treatment of dupilumab facial redness.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.